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Dear Editor
Re: Willson et al. [1]
1 Introduction
When performing a re-analysis of our study data, we found
an error in the calculation of the transition matrices in our
published analyses relating to how patients’ asthma-control
states at weekly study visits had been imputed and subse-
quently used in our original model. We have therefore re-
analysed the data using revised transition matrices and also
performed additional sensitivity analyses to confirm the
reliability and validity of the conclusions.
2 Re-Analysis of Study Data
The original Bayesian biphasic model was based on the
observed number of weekly patient transitions in the clinical
trials using six-question Asthma Control Questionnaire
(ACQ-6) results and suggested that, in both treatment arms,
there was a rapid improvement in the number of patients who
were considered to have both controlled and partly con-
trolled asthma in weeks 1–8, followed by a slower rate of
change in weeks 9–48. The re-analysis of study data using the
revised transition matrices predicted that tiotropium add-on
therapy reduced exacerbations and improved asthma control
with an incremental cost-effectiveness ratio of £28,383
(obtained at 2012 prices) per quality-adjusted life-year
(QALY) gained, which is within the commonly accepted
£20,000–£30,000 per QALY gained willingness-to-pay
threshold used in the UK [2]. There was a 52 % likelihood of
cost-effectiveness at a willingness-to-pay of £30,000 per
QALY gained and a 31 % likelihood of cost-effectiveness at
a willingness-to-pay of £20,000 per QALY gained, when
compared with usual-care treatment.
Although this re-analysis resulted in a higher overall
incremental cost-effectiveness ratio, tiotropium was still
found to be cost-effective when added to usual care in
patients whose asthma remained uncontrolled despite
treatment with high-dose inhaled glucocorticosteroids
(ICSs) with long-acting b2-agonists (LABAs) (budesonide
800 lg/formoterol fumarate 24 lg or fluticasone propi-
onate 500 lg/salmeterol 100 lg), in line with the overall
conclusions from our original publication. However, this
result was associated with greater uncertainty, reducing the
likelihood of cost-effectiveness at a willingness-to-pay of
£30,000 per QALY gained from 66 % to 52 %.
3 Additional Sensitivity Analyses
To address the increased uncertainty, we performed addi-




1 Boehringer Ingelheim, Asker, Norway
2 Division of Pulmonology, Department of Medicine,
University of Cape Town, Cape Town, South Africa
3 Respiratory Medicine, University of Oxford, Oxford, UK
4 Health Economics and Outcomes Research, Real-World
Evidence Solutions, IMS Health, London, UK
5 Boehringer Ingelheim, Ingelheim, Germany
Appl Health Econ Health Policy (2016) 14:117–118
DOI 10.1007/s40258-015-0215-0
The original model used a biphasic approach with dif-
ferent transition matrices for weeks 1–8 and 9–48. The
results of the re-analysis of study data suggest that this
approach may have underestimated the early treatment
effect and overestimated the late treatment effect. We have
therefore performed additional sensitivity analyses using a
number of modelling approaches including a Bayesian
monophasic model, a hybrid model which combines a
biphasic approach for the asthma-control states and a
monophasic approach for exacerbations, and a model using
tunnelling states. We also examined whether the ACQ
version [ACQ-6 or seven-question ACQ (ACQ-7)] affected
the results (Table 1).
The results of these additional sensitivity analyses show
that tiotropium may be cost-effective when added to usual
care in patients whose asthma remains uncontrolled despite
treatment with high-dose ICS plus LABA, irrespective of
the modelling method used, and so provides additional
confidence that the conclusions presented in our published
manuscript are valid.
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Table 1 Incremental cost-effectiveness ratios calculated during the
re-analysis of study data and additional sensitivity analyses (all values
in £ per QALY gained)
Analysis modelling approach ACQ version
ACQ-6 ACQ-7
Bayesian monophasic 20,260 17,987
Bayesian biphasic 28,383a 24,844
Hybrid 26,386 21,756
Tunnel 24,685 21,759
Obtained at 2012 prices
a Corresponds to the re-analysis of study data performed using the
methodology outlined in the original publication
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